Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at AED 33.5B, ahead of BioNTech (AED 31.3B) and Gilead Sciences (AED 27.8B). Figures as of 18 Nov 2026, 20:24 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenAED 33.5B
- Median
- AED 1.6B
- Combined market value
- AED 3.08T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | AED 33.5B | AED 883.7B | AED 1,633.77 | 2.86% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | AED 31.3B | AED 76.1B | AED 307.01 | 1.50% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | AED 27.8B | AED 771.8B | AED 622.25 | 0.49% down | 33% up | ||
| 4 | argenxARGX · Health Care | AED 12.8B | AED 218.2B | AED 3,470.39 | 0.28% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | AED 11B | AED 136B | AED 920.00 | 0.12% down | 49% up | ||
| 6 | ModernaMRNA · Health Care | AED 9.5B | AED 293.8B | AED 726.02 | 4.41% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | AED 3.3B | AED 25.3B | AED 122.23 | 0.21% up | 43% up | ||
| 8 | QiagenQGEN · Health Care | AED 3.1B | AED 37.6B | AED 182.24 | 0.26% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | AED 2.6B | AED 60.5B | AED 597.23 | 1.99% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | AED 2.1B | AED 40.4B | AED 632.71 | 6.22% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | AED 1.8B | AED 34.2B | AED 1,155.22 | 5.35% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | AED 1.8B | AED 61.5B | AED 251.97 | 0.15% up | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | AED 1.4B | AED 126.8B | AED 586.40 | 1.86% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | AED 1.3B | AED 38.1B | AED 446.70 | 0.09% up | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | AED 1.3B | AED 14.4B | AED 148.53 | 0.72% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | AED 1.2B | AED 21.3B | AED 174.86 | 5.61% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | AED 972.2M | AED 42B | AED 267.36 | 0.23% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | AED 770.8M | AED 23.5B | AED 358.92 | 0.96% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | AED 672.3M | AED 29B | AED 425.42 | 3.42% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | AED 638.9M | AED 34.1B | AED 215.15 | 1.38% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | AED 491.5M | AED 40.2B | AED 352.63 | 0.04% up | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | AED 324.4M | AED 26.2B | AED 24.63 | 7.11% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | AED 258.9M | AED 16.9B | AED 104.49 | 0.14% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | AED 119.3M | AED 26.3B | AED 294.23 | 1.48% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (AED 33.5B), BioNTech (AED 31.3B) and Gilead Sciences (AED 27.8B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 20:24 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of AED 3.08T as of 18 Nov 2026, 20:24 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.